Skip to main content
Filipe Colaço Mariz on Muck Rack

Filipe Colaço Mariz

As seen in: Nature, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Filipe Colaço

Contact Filipe Colaço, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study - npj Vaccines

|
By Penelope Gray, Filipe Colaço Mariz, Ville N. Pimenoff
| Nature Verified
Abstract Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings’ validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16–17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002–2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses.
Open in Who Shared Issue with article?

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

|
By Filipe Colaço Mariz, Deutsches Krebsforschungszentrum, Noemi Bender, Penelope Gray
| The Lancet Verified
Summary Background Quadrivalent and bivalent vaccines against oncogenic human papillomavirus (HPV) are used worldwide with different reported overall efficacies against HPV infections. Although protective concentrations of vaccine-induced antibodies are still not formally defined, we evaluated the sustainability of neutralising antibodies in vaccine trial participants 2–12 years after vaccination and the correlation with reported vaccine efficacy.
Open in Who Shared Issue with article?

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines

|
By Noemi Bender, Michael Pawlita, Devasena Anantharaman, Filipe Colaço Mariz
| Nature Verified
Abstract We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients.
Open in Who Shared Issue with article?
See all 3 articles